Welcome to our dedicated page for Vyome Holdings news (Ticker: HIND), a resource for investors and traders seeking the latest updates and insights on Vyome Holdings stock.
Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare company, marks its first day of trading on Nasdaq by ringing the opening bell, coinciding with India's 79th Independence Day. The company focuses on developing treatments for immuno-inflammatory and rare diseases in the US and global markets.
The company emphasizes its debt-free status and shareholder-aligned board structure. Vyome's pipeline targets the $100 billion immuno-inflammatory market, leveraging talent from both the US and India. The leadership team includes Chairman Krishna Gupta, Founder Shiladitya Sengupta (Associate Professor at Harvard Medical School), and Co-founder and CEO Venkat Nelabhotla.
Vyome Therapeutics has completed its previously announced merger with ReShape Lifesciences (Nasdaq: RSLS). The combined entity, to be known as Vyome Holdings, will begin trading on Nasdaq under the new ticker symbol "HIND" on August 15, 2025. Vyome is a clinical-stage healthcare company focused on developing treatments for immuno-inflammatory and rare diseases in US and global markets.